IMCR Immunocore Holdings plc
Price (delayed)
$34.52
Market cap
$1.73B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.06
Enterprise value
$1.69B
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of
Highlights
The gross profit has increased by 27% year-on-year and by 5% since the previous quarter
The revenue is up by 27% year-on-year and by 6% since the previous quarter
Immunocore Holdings's quick ratio has increased by 17% YoY but it has decreased by 13% from the previous quarter
Key stats
What are the main financial stats of IMCR
Market
Valuations
Earnings
Shares outstanding
50.02M
Market cap
$1.73B
Enterprise value
$1.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.81
Price to sales (P/S)
6.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.05
Revenue
$279.95M
EBIT
-$47.91M
EBITDA
-$42.56M
Free cash flow
$23.84M
Per share
Balance sheet
Liquidity
EPS
-$1.06
Free cash flow per share
$0.48
Book value per share
$7.18
Revenue per share
$5.6
TBVPS
$20.46
Total assets
$1.02B
Total liabilities
$664.23M
Debt
$472.95M
Equity
$359.14M
Working capital
$771.76M
Debt to equity
1.32
Current ratio
5.17
Quick ratio
4.97
Net debt/EBITDA
0.75
Margins
Efficiency
Dividend
EBITDA margin
-15.2%
Gross margin
99.4%
Net margin
-18.9%
Operating margin
-21.7%
Return on assets
-6.6%
Return on equity
-14.6%
Return on invested capital
-13%
Return on capital employed
-5.7%
Return on sales
-17.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMCR stock price
How has the Immunocore Holdings stock price performed over time
Intraday
1.83%
1 week
4.67%
1 month
-5.16%
1 year
-33.35%
YTD
-49.47%
QTD
1.86%
Financial performance
How have Immunocore Holdings's revenue and profit performed over time
Revenue
$279.95M
Gross profit
$278.29M
Operating income
-$60.71M
Net income
-$52.87M
Gross margin
99.4%
Net margin
-18.9%
The net margin has grown by 32% YoY and by 14% from the previous quarter
The gross profit has increased by 27% year-on-year and by 5% since the previous quarter
The revenue is up by 27% year-on-year and by 6% since the previous quarter
IMCR's operating income is down by 19% year-on-year and by 3.9% since the previous quarter
Growth
What is Immunocore Holdings's growth rate over time
Valuation
What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
4.81
P/S
6.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.05
The EPS has grown by 18% year-on-year and by 10% since the previous quarter
IMCR's price to book (P/B) is 37% less than its last 4 quarters average of 7.5
The equity rose by 3.6% year-on-year
The stock's price to sales (P/S) is 43% less than its last 4 quarters average of 10.6
The revenue is up by 27% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Immunocore Holdings business performance
The ROIC has soared by 60% YoY and by 57% QoQ
The return on assets has increased by 42% year-on-year and by 23% since the previous quarter
The return on sales has grown by 22% since the previous quarter but it has declined by 14% year-on-year
The ROE is up by 17% year-on-year and by 10% since the previous quarter
Dividends
What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMCR.
Financial health
How did Immunocore Holdings financials performed over time
The total assets is 54% greater than the total liabilities
The total assets has surged by 86% year-on-year and by 3% since the previous quarter
The current ratio rose by 21% YoY but it fell by 13% QoQ
The debt is 32% more than the equity
The equity rose by 3.6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.